GeneDx Announces First U.S. National Genomic Newborn Screening Initiative Launched with $14.4 Million NIH Award
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, alongside Mass General Brigham, Ariadne Labs, Boston Children’s Hospital, Albert Einstein College of Medicine, the Association of Public Health Laboratories (APHL), Case Western Reserve University, Baylor College of Medicine, and Illumina, today announced the launch of BEACONS (Building Evidence and Collaboration for GenOmics in Nationwide Newborn Screening), the nation’s first multi-state genomic newborn screening initiative.
GeneDx Appoints Lisa Gurry as Chief Business Officer to Unlock Data and Information Growth
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Lisa Gurry as Chief Business Officer (CBO), effective immediately. In this newly-created role, Gurry will lead GeneDx’s next phase of transformation, advancing data and information services across biopharma, health systems, and other partners to accelerate the company’s long-term vision of enabling precision medicine.
GeneDx Infinity™ Pioneers a New Era of Genetic Medicine with its Introduction at the American Academy of Pediatrics National Conference
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will introduce pediatricians to GeneDx’s Infinity, the company’s proprietary dataset, at the American Academy of Pediatrics (AAP) National Conference & Exhibition taking place this weekend September 26 to 30 in Denver, CO. Infinity is the largest rare disease dataset and is one of the most powerful resources to accelerate diagnosis and fuel drug discovery. It serves as the foundation for rare disease insights and powers GeneDx's ExomeDx and GenomeDx, the most trusted tests in rare disease diagnosis.
GeneDx Appoints Visionary AI and Precision Medicine Leader Dr. Thomas Fuchs to Board of Directors
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Thomas Fuchs, Dr.sc., Chief AI Officer at Eli Lilly and Company, to its board of directors.
Seer Appoints Isaac Ro to its Board of DirectorsREDWOOD CITY, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced it has appointed Isaac Ro to serve on its Board of Directors.
GeneDx to Participate in Upcoming Investor Conferences
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:
GeneDx Reports Second Quarter 2025 Financial Results and Business Highlights
GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the second quarter of 2025.
Bragar Eagel & Squire, P.C Continues Investigations on Behalf of Lineage, Proficient Auto, PetMed, and GeneDx and Encourages Investors to Contact the FirmBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In PetMed (PETS), GeneDx (WGS), Lineage (LINE), or Proficient Auto (PAL) To Contact Him Directly To Discuss Their Options
Bragar Eagel & Squire, P.C Continues Investigations on Behalf of CTO Realty, GeneDx, Quantum, and Proficient Auto and Encourages Investors to Contact the FirmBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In CTO Realty (CTO), GeneDx (WGS), Quantum (QMCO), or Proficient Auto (PAL) To Contact Him Directly To Discuss Their Options
Bragar Eagel & Squire, P.C Continues Investigations on Behalf of PetMed, GeneDx, Lineage, and Proficient Auto and Encourages Investors to Contact the FirmBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In PetMed (PETS), GeneDx (WGS), Lineage (LINE), or Proficient Auto (PAL) To Contact Him Directly To Discuss Their Options
GeneDx to Report Second Quarter 2025 Financial Results on Tuesday, July 29, 2025
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the second quarter of 2025 before the market opens on Tuesday, July 29, 2025. Management will host a conference call that day to discuss second quarter 2025 financial and operating results at 8:30 a.m. Eastern Time.
